AUS
NZ
UK
CA
USA
IND
Highlights
- Multiple analysts have revised their earnings estimates for Owens & Minor, adjusting price targets amid varying ratings.
- The company's stock has seen fluctuations, with significant institutional investment indicating continued industry interest.
- Owens & Minor maintains its focus as a healthcare solutions provider across manufacturing, home health supply, and perioperative services.
Owens & Minor, Inc. (NYSE:OMI), a prominent player in the healthcare solutions industry, is under renewed scrutiny from investment analysts, leading to notable shifts in earnings projections and stock ratings. Recently, analysts at Leerink Partners revised their Q2 2025 earnings per share (EPS) estimates for Owens & Minor, reducing it sharply from $0.39 to $0.01. This revision follows a series of adjustments, reflecting broader market sentiments and the company's ongoing strategic actions within the healthcare sector.
In addition to Leerink Partners, other research firms have also modified their outlooks. Barclays decreased the target price from $18.00 to $14.00, maintaining an "equal weight" rating. Meanwhile, Citigroup adjusted its target from $21.00 to $18.50, albeit retaining a "buy" rating. UBS Group similarly revised its price objective, lowering it from $25.00 to $13.00, yet keeping a "buy" stance. Robert W. Baird set a neutral outlook, adjusting the target price from $15.00 to $14.00. The overall consensus from MarketBeat.com positions Owens & Minor with an average rating of "Hold" and an average price target of $16.79, indicating a balanced perspective from market analysts amidst varying estimates and ratings.
The company's stock opened at $6.23 on Monday, reflecting a dip of 2.7% amid fluctuating market dynamics. Currently, Owens & Minor has a market capitalization of approximately $480.01 million, with a price-to-earnings ratio (P/E) of -9.58, highlighting challenges within its financial framework. Despite these dynamics, Owens & Minor continues to draw interest from institutional investors. For instance, UBS Asset Management Americas’ distinct unit increased its holdings by 29.6% in the fourth quarter. Other hedge funds and institutional players, including Voloridge Investment Management, Squarepoint Ops, and ProShare Advisors LLC, have also adjusted their stakes in recent quarters, indicating active engagement and strategic positioning within the healthcare investment landscape.
Owens & Minor operates through its key segments: Products and Healthcare Services, and Patient Direct, supporting care from hospital settings to home healthcare delivery. The company's focus on product manufacturing and delivery, coupled with home health supply and perioperative services, underscores its commitment to healthcare innovation and service delivery.
Given these insights, Owens & Minor continues to navigate its path amidst changing market conditions, analyst opinions, and strategic investor interests. With a steadfast focus on healthcare solutions, the company remains a significant entity within its sector, reflecting ongoing adaptation and resilience.
